Paper28292559
Pathological characterisation of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program.
Vermeulen MA and 14 others. Eur J Cancer, 2017. Cited by 70 papers, by iCite.
Cite this record
ConductScience Library. Pathological characterisation of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. Papers, record 28292559. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28292559
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Pathological characterisation of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program.
- PubMed
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Breast Neoplasms, Male | Major topic |
| Carcinoma | Major topic |
| Aged | |
| Biomarkers, Tumor | |
| Carcinoma, Ductal, Breast | |
| Carcinoma, Lobular | |
| Fibrosis | |
| Humans | |
| Immunohistochemistry | |
| Lymphocytes, Tumor-Infiltrating | |
| Male | |
| Middle Aged | |
| Mitotic Index | |
| Prognosis | |
| Survival Analysis |
Source PubMed
Cited by39
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 70 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42882846 | Histological Subtype Provides Limited Prognostic Information in Grade 1 Invasive Breast Carcinoma: A Retrospective Cohort Study. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42882846 | PubMed |
| 41947199 | Transcriptomic deconvolution reveals prognostic immune signatures and immunotherapy-responsive subtypes in male breast cancer. | Breast Cancer Res | 2026 | https://conductscience.org/library/papers/41947199 | PubMed |
| 41575527 | Validation of IHC4 + C for male breast cancer. | Virchows Arch | 2026 | https://conductscience.org/library/papers/41575527 | PubMed |
| 41097794 | Current Perspectives on Non-Metastatic Male Breast Cancer: Genetics, Biology, and Treatment Advances: A Systematic Review. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/41097794 | PubMed |
| 40234892 | Redefining therapeutic landscapes: clinicopathological insights into low and ultra-low HER2 expression in male breast cancer. | Diagn Pathol | 2025 | https://conductscience.org/library/papers/40234892 | PubMed |
| 39377609 | Trends and efficacy of omitting axillary lymph node dissection in early-stage male breast cancer with limited nodal involvement: A population-based cohort study. | Cancer Med | 2024 | https://conductscience.org/library/papers/39377609 | PubMed |
| 39365001 | Clinicopathologic Features and Prognoses of Male Patients With Breast Cancer. | Am J Mens Health | 2024 | https://conductscience.org/library/papers/39365001 | PubMed |
| 39095633 | Influence of tumour grade on disease survival in male breast cancer patients: a systematic review. | Breast Cancer Res Treat | 2024 | https://conductscience.org/library/papers/39095633 | PubMed |
| 38339299 | HER2-Low Expression in Male Breast Cancer: Results from a Multicenter Series in Italy. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/38339299 | PubMed |
| 37085843 | The prediction of distant metastasis risk for male breast cancer patients based on an interpretable machine learning model. | BMC Med Inform Decis Mak | 2023 | https://conductscience.org/library/papers/37085843 | PubMed |
| 36614261 | Tumor Microenvironment in Male Breast Carcinoma with Emphasis on Tumor Infiltrating Lymphocytes and PD-L1 Expression. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/36614261 | PubMed |
| 35695928 | Tumor budding and fibrotic focus-proposed grading system for tumor budding in invasive carcinoma no special type of the breast. | Virchows Arch | 2022 | https://conductscience.org/library/papers/35695928 | PubMed |
| 35181590 | High-throughput Proteomic Profiling of Male Breast Cancer Tissue. | Cancer Genomics Proteomics | 2022 | https://conductscience.org/library/papers/35181590 | PubMed |
| 35117121 | Intracystic papillary breast carcinoma with DCIS in a man: a case report. | Transl Cancer Res | 2019 | https://conductscience.org/library/papers/35117121 | PubMed |
| 34733614 | A biomarker study in Peruvian males with breast cancer. | World J Clin Oncol | 2021 | https://conductscience.org/library/papers/34733614 | PubMed |
| 34572741 | Transcriptome of Male Breast Cancer Matched with Germline Profiling Reveals Novel Molecular Subtypes with Possible Clinical Relevance. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/34572741 | PubMed |
| 34458944 | Male breast cancer: an update. | Virchows Arch | 2022 | https://conductscience.org/library/papers/34458944 | PubMed |
| 34079019 | Comparison between male and female breast cancer survival using propensity score matching analysis. | Sci Rep | 2021 | https://conductscience.org/library/papers/34079019 | PubMed |
| 33991247 | Prognostic relevance of Ki67 expression in primary male breast cancer: determination of cut-off points by different evaluation methods and statistical examinations. | J Cancer Res Clin Oncol | 2022 | https://conductscience.org/library/papers/33991247 | PubMed |
| 33974127 | Cytoplasmic DDX3 as prognosticator in male breast cancer. | Virchows Arch | 2021 | https://conductscience.org/library/papers/33974127 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| ERBB2 | 2064 | PubTator's text mining | https://conductscience.org/library/genes/2064 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/28292559
GET https://conductscience.org/api/papers/v1/28292559/cited_by?page=2